A detailed history of Janus Henderson Group PLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 26,159 shares of SAGE stock, worth $281,994. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,159
Previous 26,159 -0.0%
Holding current value
$281,994
Previous $566,000 13.43%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$17.1 - $22.26 $684 - $890
-40 Reduced 0.15%
26,159 $566,000
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $67 - $195
4 Added 0.02%
26,199 $539,000
Q2 2023

Aug 14, 2023

SELL
$40.65 - $59.54 $16 Million - $23.4 Million
-392,551 Reduced 93.74%
26,195 $1.23 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $46.57 $7.47 Million - $9.34 Million
-200,544 Reduced 32.38%
418,746 $17.6 Million
Q4 2022

Feb 14, 2023

SELL
$32.2 - $43.61 $3.61 Million - $4.89 Million
-112,133 Reduced 15.33%
619,290 $23.6 Million
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $1.15 Million - $1.54 Million
-35,626 Reduced 4.64%
731,423 $28.6 Million
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $7.24 Million - $9.99 Million
-262,904 Reduced 25.53%
767,049 $24.8 Million
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $1.69 Million - $2.51 Million
54,971 Added 5.64%
1,029,953 $34.1 Million
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $2.82 Million - $3.58 Million
-76,011 Reduced 7.23%
974,982 $41.5 Million
Q3 2021

Nov 16, 2021

SELL
$40.26 - $57.37 $24.5 Million - $35 Million
-609,460 Reduced 36.7%
1,050,993 $46.6 Million
Q2 2021

Aug 16, 2021

SELL
$54.88 - $79.29 $11.7 Million - $16.9 Million
-212,929 Reduced 11.37%
1,660,453 $94.3 Million
Q1 2021

May 17, 2021

SELL
$70.65 - $96.76 $7.45 Million - $10.2 Million
-105,429 Reduced 5.33%
1,873,382 $140 Million
Q4 2020

Feb 16, 2021

BUY
$58.41 - $89.06 $21 Million - $32 Million
359,110 Added 22.17%
1,978,811 $171 Million
Q3 2020

Nov 16, 2020

BUY
$41.13 - $62.45 $6.58 Million - $9.99 Million
160,025 Added 10.96%
1,619,701 $99 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $1.87 Million - $3.1 Million
71,881 Added 5.18%
1,459,676 $60.7 Million
Q1 2020

May 14, 2020

SELL
$26.15 - $77.24 $26.8 Million - $79.3 Million
-1,026,417 Reduced 42.52%
1,387,795 $39.9 Million
Q4 2019

Feb 18, 2020

BUY
$60.18 - $154.77 $24 Million - $61.7 Million
398,808 Added 19.79%
2,414,212 $174 Million
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $19.9 Million - $27 Million
141,996 Added 7.58%
2,015,404 $283 Million
Q2 2019

Jul 31, 2019

BUY
$157.85 - $183.09 $32.3 Million - $37.5 Million
204,779 Added 12.27%
1,873,408 $343 Million
Q1 2019

Apr 30, 2019

BUY
$89.33 - $163.65 $121 Million - $223 Million
1,359,947 Added 440.57%
1,668,629 $265 Million
Q4 2018

Feb 06, 2019

BUY
$81.94 - $139.71 $3.61 Million - $6.15 Million
44,019 Added 16.63%
308,682 $29.6 Million
Q3 2018

Nov 09, 2018

BUY
$138.11 - $169.04 $12.1 Million - $14.8 Million
87,427 Added 49.33%
264,663 $37.4 Million
Q2 2018

Aug 10, 2018

SELL
$140.36 - $175.76 $1.04 Million - $1.3 Million
-7,413 Reduced 4.01%
177,236 $27.7 Million
Q1 2018

May 14, 2018

SELL
$152.15 - $192.33 $1.88 Million - $2.38 Million
-12,386 Reduced 6.29%
184,649 $29.7 Million
Q4 2017

Feb 09, 2018

BUY
$60.72 - $167.34 $12 Million - $33 Million
197,035
197,035 $32.5 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $641M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.